Prospects for CD40 directed experimental therapy of human

If you want to confirm some technical details before you order,
just need to send a message or e-mail: [email protected].
Then our professional sales staff will contact you within 2 hours.

Multifunctional CD40L: pro- and anti-neoplastic activity .

The CD40 ligand is a type I transmembrane protein that belongs to a tumor necrosis factor (TNF) superfamily. It is present not only on the surface of activated CD4+ T cells, B cells, blood platelets,...

Anti-CD40-induced inflammatory E-cadherin+ dendritic cells .

CD40 is a tumour necrosis factor receptor superfamily member that is expressed on antigen-presenting cells (APCs) such as dendritic cells (DC), B Anti-CD40-induced inflammatory E-cadherin+ dendritic cells enhance T cell responses and antitumour immunity in murine Lewis lung carcinoma | springermedizin.de

Myeloma CD40 - ユーザーTOP|近鉄ケーブルネットワー

al;Prospects for CD40-directed experimental therapy of human cancer. Cancer Gene Ther. 2003 Jan;10 ... An agonist anti-human CD40 monoclonal antibody that induces ...

Dr. Marvin Stone, Oncologist in Dallas, TX | US News Docto

Dr. Marvin Stone is a Oncologist in Dallas, TX. ... Prospects for CD40-directed experimental therapy of human cancer. ... Anti-CD40 antibody binding modulates human multiple myeloma clonogenicity ...

A phase I multidose study of dacetuzumab (SGN-40 .

Design and Methods. This open-label, phase I study used a traditional 3+3 dose escalation scheme. The maximum tolerated dose (MTD) was the highest dacetuzumab dose at which fewer than one third of patients in a cohort experienced a dose-limiting toxicity (DLT).

Anti-CD40 agonist antibodies: preclinical and clinical .

Despite promising results with this initial study, it was not until several years later with the development of anti-CD40 mAbs that interest in targeting CD40 for anti-cancer therapy resurfaced. CP-870,893 (Pfizer) is a fully human CD40 agonist IgG2 mAb that exhibits immune-mediated and non-immune mediated effects on tumor cell death (26, 27 ...

Prospects for CD40-directed experimental therapy of human .

CD40-related treatment approaches have been considered for the experimental therapy of human leukemias, lymphomas, and multiple myeloma, based on findings that CD40 binding by its natural ligand (CD40L), CD154, led to growth modulation of malignant B cells.

CD40 is overexpressed by HPV16/18-E6 positive cervical .

Read "CD40 is overexpressed by HPV16/18-E6 positive cervical carcinoma and correlated with clinical parameters and vascular density, Cancer Epidemiology" on DeepDyve, the largest online rental service for scholarly research with thousands of academic publications available at your fingertips.

Induced activation in dendritic cells - Baylor College of .

The present invention is directed to a composition and method which to treat diseases and to enhance a regulated immune response. More particularly, the present invention is drawn to compositions that are based on dendritic cells modified to express an inducible form of a costimulatory polypeptide.

A phase II study of dacetuzumab (SGN-40) in patients with .

Patients with DLBCL who are ineligible for or have relapsed after aggressive salvage chemotherapy have a poor prognosis. CD40 is expressed on multiple B-cell neoplasms including DLBCL and is a potential target for immunotherapy. Dacetuzumab (SGN-40), a non-blocking, partial agonist, humanized IgG1, anti-CD40 monoclonal antibody, has previously demonstrated anti-lymphoma activity in a phase I ...

Clinical Activity and Immune Modulation in Cancer Patients .

The cell-surface molecule CD40 activates antigen-presenting cells and enhances immune responses. CD40 is also expressed by solid tumors, but its engagement results in apoptosis. CP-870,893, a fully human and selective CD40 agonist monoclonal antibody (mAb), was tested for safety in a phase I dose ...

Multiple effects of CD40–CD40L axis in immunity against .

Multiple effects of CD40-CD40L axis in immunity against infection and cancer Anjuman Ara,1,2 Khawaja Ashfaque Ahmed,1,2 Jim Xiang1,2 1Cancer Research Cluster, Saskatchewan Cancer Agency, Saskatoon, Saskatchewan, Canada; 2Division of Oncology, College of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada Abstract: CD8+ cytotoxic T lymphocyte (CTL) protects against infection ...


INDUCED ACTIVATION IN DENDRITIC CELLS ... pages 421 - 429, XP004466621 TONG ET AL.: 'Prospects for CD40-directed experimental therapy of human cancer' CANCER GENE THER. vol ... 'Prolonged maturation and enhanced transduction of dendritic cells migrated from human skin explants after in situ delivery of CD40 ...

Role for CD40L in the therapy of human cancer | SpringerLi

Its natural ligand (CD40 ligand, CD40L), CD154, a member of the tumor necrosis factor (TNF) family, is mainly expressed on activated CD4 + T lymphocytes. A direct growth-inhibitory effect can be found when ligated CD40 is on human breast, ovarian, cervical, bladder, non-small cell lung, and squamous epithelial carcinoma cells.

Target Therapy in Hematological Malignances: New .

Apart from radio- and chemotherapy, monoclonal antibodies (MoAbs) represent a new, more selective tool in the treatment of hematological malignancies. MoAbs bind with the specific antigens of the tumors. This interaction is a basis for targeted therapies which exhibit few side effects and significant antitumor activity. This review provides an overview of the functional characteristics of ...

Therapeutic Interventions Targeting CD40L (CD154) and CD40 .

CD40 was originally identified as a receptor on B-cells that delivers contact-dependent T helper signals to B-cells through interaction with CD40 ligand (CD40L, CD154). The pivotal role played by...

(PDF) Preclinical pharmacokinetics, pharmacodynamics, and .

Preclinical pharmacokinetics, pharmacodynamics, and activity of a humanized anti-CD40 antibody (SGN-40) in rodents and non-human primates. British Journal of Pharmacology, 2006. T. Gelzleichter. Sean Kelley. Dong Xie. Walter Darbonne. Ferhan Qureshi. Iqbal Grewal.

Age-Related Changes on CD40 Promotor Methylation and .

120 one-day-old breeder cocks, included 15 cages of 8 birds each, were fed to learn the aging's effect on chicken’s thymus immunity. At 2 (2-W) and 40 (40-W) weeks of age, one chicken each cage was randomly chosen and slaughtered to get the thymus sample. The results showed that thymus weight and morphology of 40-W group were far different from that of 2-W group, and exhibited a property of ...

Prospects for modulating the CD40/CD40L pathway in the .

Prospects for modulating the CD40/CD40L pathway in the therapy of the hyper-IgM syndrome Show all authors. ... a human CD40 agonist monoclonal Ab, ... a full evaluation of therapy with CD40 agonists is important for HIGM therapy even if CD40 agonist does not correct the immunodeficiency.

Targeting the Lymphotoxin-β Receptor with Agonist .

The lymphotoxin-β receptor (LTβR) is a tumor necrosis factor receptor family member critical for the development and maintenance of various lymphoid microenvironments. Herein, we show that agonistic anti-LTβR monoclonal antibody (mAb) CBE11 inhibited tumor growth in xenograft models and potentiated tumor responses to chemotherapeutic agents.

Preclinical pharmacokinetics, pharmacodynamics, and .

SGN-40 binds the human CD40 receptor with a high ... LELE S., FANSLOW W., REPASKY E.A. Recombinant CD40 ligand therapy has significant antitumor effects on CD40-positive ovarian tumor xenografts grown in SCID mice and demonstrates an augmented effect with cisplatin. ... STONE M.J. Prospects for CD40-directed experimental therapy of human cancer ...